Completed PHASE2 INTERVENTIONAL 2-arm NCT00816894

D-serine Monotherapy for Schizophrenia

D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia

Sponsor: Herzog Hospital

Updated 5 times since 2017 Last updated: Dec 9, 2013 Started: Jan 31, 2009 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Schizophrenia and is currently completed. Herzog Hospital leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Herzog Hospital
Israel Science Foundation

Data source: Herzog Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jerusalem, Israel